The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 6, 2008, Pages 1339-1343

  Abbas, Sascha ^a   Linseisen, Jakob ^a   Slanger, Tracy ^a   Kropp, Silke ^a   Mutschelknauss, Elke Jonny ^b   Flesch Janys, Dieter ^b   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D; VITAMIN D BINDING PROTEIN;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; GC GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; TUMOR GENE; VITAMIN BLOOD LEVEL;

AGED; ALLELES; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 53349174521     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0162     Document Type: Article

References (23)

1. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006;102:156-62.
2. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45-59.
3. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003;88:695-705.
4. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008;29:93-9.
5. Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1991-7.
6. Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:2335-9.
7. Yamamoto N, Naraparaju VR. Role of vitamin D3-binding protein in activation of mouse macrophages. J Immunol 1996;157:1744-9.
8. Kisker O, Onizuka S, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
9. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 2008;122:461-7.
10. Braun A, Bichlmaier R, Cleve H. Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types. Hum Genet 1992;89:401-6.
11. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993;92:183-8.
12. Lauridsen AL, Vestergaard P, Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem 2001;47:753-6.
13. Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005;77:15-22.
14. Lauridsen AL, Vestergaard P, Hermann AP, Moller HJ, Mosekilde L, Nexo E. Female premenopausal fracture risk is associated with Gc phenotype. J Bone Miner Res 2004;19:875-81.
15. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2007;9:R9.
16. Rowling MJ, Kemmis CM, Taffany DA, Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006;136:2754-9.
17. Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 2007;28:1373-82.
18. Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells. J Immunol 1993;151:2794-802.
19. Yamamoto N. Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. Mol Immunol 1996;33:1157-64.
20. James SY, Mackay AG, Binderup L, Colston KW. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 1994;141:555-63.
21. Swami S, Krishnan AV, Feldman D. 1A,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 2000;6:3371-9.
22. Kailajarvi ME, Salminen EK, Paija OM, Virtanent AM, Leino AE, Irjala KA. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004;24:1271-4.
23. Gao Y, Shimizu M, Yamada S, Ozaki Y, Aso T. The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocr J 1993;40:737-42.